FAM184A

Across TCGA pan-cancer cohorts, FAM184A mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated FAM184A data layer compared with 23 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher FAM184A mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated FAM184A expression acts as an unfavorable survival marker, although some lineages such as LSCC and GBM show a favorable association.

LUAD, LSCC, and GBM are the cancer types where FAM184A mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Tertile	All	0.786	0.922	.009	6	view →
LSCC	DFS	Median	II,III,IV	1.000	0.431	.042	2	view →
GBM	DFS	Tertile	All	0.882	0.656	.041	1	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

FAM184A–LUAD (DFS)

Open the LUAD breakdown →